CAREDX, INC. (CDNA) Scorecard
- 2026-Q2: Total return Win; Revenue growth Win; EPS growth Win.
- 2026-Q1: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Win; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Win; EPS growth Lose.
67/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 7 wins, 5 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q23/3 |
WinCDNA / S&P 64.17% / 15.20% |
WinCDNA / S&P 34.41% / 15.00% |
WinCDNA / S&P 97.14% / 50.40% |
| 2026-Q11/3 |
LoseCDNA / S&P -7.86% / -4.33% |
WinCDNA / S&P 19.17% / 11.30% |
LoseCDNA / S&P -114.29% / 27.70% |
| 2025-Q42/3 |
WinCDNA / S&P 29.57% / 2.65% |
WinCDNA / S&P 13.79% / 9.00% |
LoseCDNA / S&P -143.01% / 13.40% |
| 2025-Q31/3 |
LoseCDNA / S&P -25.59% / 8.12% |
WinCDNA / S&P 14.46% / 4.61% |
LoseCDNA / S&P -144.60% / 13.45% |
| 2025-Q21/3 |
LoseCDNA / S&P 10.08% / 10.94% |
WinCDNA / S&P 14.72% / 4.83% |
LoseCDNA / S&P -133.87% / 10.63% |
| 2025-Q11/3 |
LoseCDNA / S&P -17.09% / -4.27% |
WinCDNA / S&P 25.92% / 4.98% |
LoseCDNA / S&P -132.28% / 10.57% |
| 2024-Q41/3 |
LoseCDNA / S&P -31.43% / 2.41% |
WinCDNA / S&P 19.07% / 5.25% |
LoseCDNA / S&P -126.35% / 6.15% |
| 2024-Q32/3 |
WinCDNA / S&P 101.06% / 5.89% |
LoseCDNA / S&P 5.26% / 5.89% |
WinCDNA / S&P 70.83% / 6.11% |
| 2024-Q22/3 |
WinCDNA / S&P 46.65% / 4.28% |
LoseCDNA / S&P -3.95% / 5.38% |
WinCDNA / S&P 97.45% / 5.12% |
| 2024-Q11/3 |
LoseCDNA / S&P -11.75% / 10.56% |
LoseCDNA / S&P -13.93% / 5.71% |
WinCDNA / S&P 128.29% / 5.59% |
| 2023-Q42/3 |
WinCDNA / S&P 71.43% / 11.69% |
LoseCDNA / S&P -12.89% / 6.81% |
WinCDNA / S&P 143.45% / 7.78% |
| 2023-Q31/3 |
LoseCDNA / S&P -17.65% / -3.27% |
LoseCDNA / S&P -6.74% / 7.52% |
WinCDNA / S&P 19.15% / -5.03% |
| 2023-Q21/3 |
LoseCDNA / S&P -7.00% / 8.74% |
LoseCDNA / S&P -1.76% / 9.50% |
WinCDNA / S&P 18.94% / -8.57% |
| 2023-Q11/3 |
LoseCDNA / S&P -19.89% / 7.50% |
LoseCDNA / S&P 3.64% / 10.77% |
WinCDNA / S&P 60.00% / -15.69% |
| 2022-Q41/3 |
LoseCDNA / S&P -32.96% / 7.56% |
LoseCDNA / S&P 8.57% / 11.88% |
WinCDNA / S&P 145.76% / -17.99% |
| 2022-Q32/3 |
LoseCDNA / S&P -20.76% / -4.88% |
WinCDNA / S&P 15.52% / 13.47% |
WinCDNA / S&P 302.86% / -1.41% |
| 2022-Q22/3 |
LoseCDNA / S&P -41.93% / -16.10% |
WinCDNA / S&P 24.16% / 13.71% |
WinCDNA / S&P 633.33% / 11.04% |
| 2022-Q12/3 |
LoseCDNA / S&P -18.67% / -4.60% |
WinCDNA / S&P 39.42% / 15.97% |
WinCDNA / S&P 227.59% / 42.23% |
| 2021-Q41/3 |
LoseCDNA / S&P -28.23% / 11.03% |
WinCDNA / S&P 54.22% / 15.00% |
LoseCDNA / S&P 40.48% / 96.40% |
| 2021-Q31/3 |
LoseCDNA / S&P -30.76% / 0.58% |
WinCDNA / S&P 62.85% / 10.77% |
LoseCDNA / S&P -23.91% / 69.42% |
| 2021-Q22/3 |
WinCDNA / S&P 34.41% / 8.55% |
WinCDNA / S&P 69.28% / 6.58% |
LoseCDNA / S&P -59.09% / 51.81% |
| 2021-Q11/3 |
LoseCDNA / S&P -6.02% / 6.17% |
WinCDNA / S&P 58.62% / -1.06% |
LoseCDNA / S&P -39.58% / 7.39% |
| 2020-Q43/3 |
WinCDNA / S&P 90.96% / 12.15% |
WinCDNA / S&P 51.25% / -3.72% |
WinCDNA / S&P -19.23% / -33.42% |
| 2020-Q32/3 |
LoseCDNA / S&P 7.08% / 8.93% |
WinCDNA / S&P 47.59% / -2.04% |
WinCDNA / S&P 0.00% / -27.10% |
| 2020-Q22/3 |
WinCDNA / S&P 62.30% / 20.54% |
WinCDNA / S&P 46.69% / -0.46% |
LoseCDNA / S&P -54.17% / -27.11% |
| 2020-Q12/3 |
WinCDNA / S&P 1.21% / -19.60% |
WinCDNA / S&P 57.59% / 3.47% |
LoseCDNA / S&P -58.97% / -14.75% |
| 2019-Q41/3 |
LoseCDNA / S&P -4.60% / 9.07% |
WinCDNA / S&P 65.95% / 5.36% |
LoseCDNA / S&P -59.69% / 2.99% |
| 2019-Q31/3 |
LoseCDNA / S&P -37.18% / 1.70% |
WinCDNA / S&P 75.03% / 5.02% |
LoseCDNA / S&P -81.82% / 0.21% |
| 2019-Q22/3 |
WinCDNA / S&P 14.18% / 4.30% |
WinCDNA / S&P 80.54% / 6.64% |
LoseCDNA / S&P -63.36% / 8.65% |
| 2019-Q12/3 |
WinCDNA / S&P 25.38% / 13.65% |
WinCDNA / S&P 74.23% / 8.12% |
LoseCDNA / S&P -51.45% / 14.29% |
| 2018-Q42/3 |
WinCDNA / S&P -12.86% / -13.52% |
WinCDNA / S&P 58.45% / 9.05% |
LoseCDNA / S&P -45.57% / 18.23% |
| 2018-Q33/3 |
WinCDNA / S&P 135.70% / 7.71% |
WinCDNA / S&P 40.45% / 10.21% |
WinCDNA / S&P 36.02% / 19.06% |
| 2018-Q23/3 |
WinCDNA / S&P 53.58% / 3.43% |
WinCDNA / S&P 20.45% / 9.03% |
WinCDNA / S&P 75.84% / 14.46% |
| 2018-Q13/3 |
WinCDNA / S&P 8.58% / -0.76% |
WinCDNA / S&P 11.26% / 7.68% |
WinCDNA / S&P 16.43% / 12.46% |
| 2017-Q42/3 |
WinCDNA / S&P 98.38% / 6.64% |
WinCDNA / S&P 18.93% / 7.03% |
LoseCDNA / S&P -9.54% / 13.82% |
| 2017-Q32/3 |
WinCDNA / S&P 233.33% / 4.48% |
WinCDNA / S&P 28.17% / 5.68% |
LoseCDNA / S&P -16.96% / 17.57% |
| 2017-Q21/3 |
LoseCDNA / S&P -20.71% / 3.09% |
WinCDNA / S&P 51.03% / 4.83% |
LoseCDNA / S&P -34.36% / 17.74% |
| 2017-Q12/3 |
LoseCDNA / S&P -48.15% / 6.07% |
WinCDNA / S&P 66.07% / 3.67% |
WinCDNA / S&P 16.95% / 13.32% |
| 2016-Q41/3 |
LoseCDNA / S&P -23.94% / 3.82% |
WinCDNA / S&P 44.37% / 2.09% |
LoseCDNA / S&P CDNA unavailable / 7.05% |
| 2016-Q31/3 |
LoseCDNA / S&P -17.63% / 3.85% |
WinCDNA / S&P 23.68% / 0.20% |
LoseCDNA / S&P CDNA unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | CDNA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 283.31% | 20.78% |
| Annualized return | 283.31% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | CDNA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -30.63% | 83.14% |
| Annualized return | -7.05% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | CDNA total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 1058.41% | 319.30% |
| Annualized return | 27.76% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celcuity Inc. (CELC) | United States | $3.887B | -22.62 |
| VERACYTE, INC. (VCYT) | United States | $3.904B | 41.21 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| GRAIL, Inc. (GRAL) | United States | $5.591B | -7.78 |
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| BIODESIX INC (BDSX) | United States | $0.312B |